Orphazyme burned through millions of dollars in futile fight for success
Biotech is an expensive business, something Orphazyme can attest to. Over the years, it spent hundreds of millions of dollars developing its main asset, without ever crossing the finish line.
.jpg)
by christian bundgaard, translated by catherine brett
Despite its best efforts, biotech firm Orphazyme never managed to make an approved drug out of its candidate arimoclomol. This was despite the firm spending billions of kroner on the candidate.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Orphazyme reports USD 90m deficit for 2021
For subscribers
.jpg)
Orphazyme CEO on sale: "It’s sad, but we tried everything"
For subscribers
Orphazyme is now officially in American hands
For subscribers
.jpg&w=384&q=75)
